Announced details
First-line treatment for advanced or recurrent EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Disease control rate (DCR): 100%; objective response rate (ORR): 69.2%; median progression-free survival (PFS): 23.1 months. No Grade 4–5 adverse events or treatment-related deaths were observed.
26 patients enrolled (Phase 2 trial)
The company is advancing the development of DFP-14323.
No impact on business performance stated
The company does not address Contract Value / Offering price.
Therapeutic Advances in Medical Oncology、Volume 18, 2026、DOI: 10.1177/17588359261483551
| Item | Details |
|---|---|
| Names of Products / Services Covered | DFP-14323 (generic name: ubenimex), Combination therapy with low-dose afatinib |
| Relationship with the Company | The company is advancing the development of DFP-14323. |
| Applicable area | First-line treatment for advanced or recurrent EGFR mutation-positive non-small-cell lung cancer (NSCLC) |
| Quantitative Effects | Disease control rate (DCR): 100%; objective response rate (ORR): 69.2%; median progression-free survival (PFS): 23.1 months. No Grade 4–5 adverse events or treatment-related deaths were observed. |
| Usage history | 26 patients enrolled (Phase 2 trial) |
| Impact on Business Performance | No impact on business performance stated |
| Source | Therapeutic Advances in Medical Oncology、Volume 18, 2026、DOI: 10.1177/17588359261483551 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The clinical trial results previously presented at academic conferences and other venues have now been formally reported in a peer-reviewed international medical journal. The company also stated that it will advance the treatment's clinical development going forward.